Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients"
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ahmed Hassan shaaban, MD
Beni-Suef University
Study Director - Raghda RS Hussein, PHD
Beni-Suef University
Study Director - Reham shehab El-Nemr, MD
Fayoum University
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fayoum Oncology Center
Al Fayyum, Egypt
Not, yet, recruiting - Beni-Suef University Hospital
Banī Suwayf, Egypt
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Oct 2021
- Primary completion
- 30 Dec 2023
- Completion
- 30 Dec 2024
- Last update posted
- 2 Nov 2022
- Registered enrollment
- 60
- Registry id
- NCT05103644
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.